1 Min Read
May 12 (Reuters) -
* Immusant announces publication of positive data from phase 1 trials of Nexvax2 in celiac disease patients Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.